Rationale: Both cardiomyocyte-restricted proteasome functional enhancement and pharmacological proteasome inhibition (PSMI) were shown to attenuate myocardial ischemia/reperfusion (I/R) injury. The role of cardiac proteasome dysfunction during I/R and the perspective to diminish I/R injury by manipulating proteasome function remain unclear.
T he ubiquitin-proteasome system (UPS) mediates the degradation of most proteins in the cell. The UPS is pivotal to protein quality control (PQC) because it is responsible for degrading all abnormal proteins, including terminally misfolded proteins. Through targeted degradation of normal proteins that are no longer needed (eg, activated kinases and their regulators), the UPS also regulates virtually all cellular processes. 1,2 PQC and the regulatory protein degradation are essential to maintaining normal cell function and cell survival; hence, cardiac UPS dysfunction can cause not only cardiac malfunction but also increased cardiomyocyte death in the heart. [3] [4] [5] In general, UPS-mediated proteolysis involves ubiquitination of target proteins and the degradation of the ubiquitinated proteins by the proteasome. The most studied proteasome is the 26S proteasome which consists of a 20S proteasome flanked by the 19S proteasome at one or both ends. Proteasomal proteolysis takes place in the interior chamber of the 20S. The 20S is composed of an axial stack of four rings: 2 antiparallel inner ␤ rings flanked by 2 outer ␣ rings. Each ␣ or ␤ ring is formed by 7 subunits, known as ␣1 through ␣7 and ␤1 through ␤7. Three peptidase activities: chymotrypsin-like, trypsin-like, and caspaselike, have been identified in eukaryotic proteasomes, residing respectively in ␤5, ␤2, and ␤1 subunits. Most proteasome inhibitors, including the clinically used bortezomib, target the ␤5 subunit, inhibit its catalytic activity, and thereby inhibit the 20S proteasome. 2 
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Based largely on the in vitro proteasome peptidase activity assays, alterations of proteasome function were associated with a variety of cardiac pathological conditions, 6, 7 for example, load-dependent cardiac disorders, 8 -10 hypertrophic or dilated cardiomyopathy, 10 -14 and ischemic heart disease. 14 -20 Apparently, the altered proteasome activities in a pathological condition can be a pathogenic factor contributing to progression of the disease, a compensatory response, or simply an epiphenomenon; hence, it is important to test these possibilities in a given disease, for a better understanding of the role of UPS dysfunction in pathogenesis. To do so, we must answer at least 2 important questions: (1) is the altered proteasome function sufficient to maintain proteostasis in the cell, and (2) what is its impact on the progression of the disease?
To help examine questions like the first one, we previously developed a stable transgenic (tg) mouse model expressing a modified green fluorescence protein (GFPdgn) that is a verified surrogate substrate of the UPS. 21 We used the GFPdgn tg mice to unveil proteasome functional insufficiency (PFI), despite a marked increase of proteasome peptidase activities, in the heart of mouse models of cardiac proteinopathy. 22, 23 However, proteasome functional sufficiency has not been determined in many other cardiac pathological conditions, for example, myocardial ischemia/ reperfusion (I/R) injury, although most reports show decreased proteasome peptidase activities in I/R hearts. 16, 20, 24 Thus, in the first part of the present study, we inquired PFI occurrence in mouse hearts with acute regional myocardial I/R in vivo.
To answer the second question, we must manipulate proteasome function specifically in cardiomyocytes without affecting other cell types of the heart and other organs/ systems. However, an animal model of cardiomyocyterestricted proteasomal inhibition (CR-PSMI) has not been described although we have recently reported a mouse model of cardiomyocyte-restricted proteasome functional enhancement. 25, 26 We used the latter model to demonstrate that proteasome functional enhancement in cardiomyocytes protects against acute myocardial I/R injury, 26 contradicting to several reports which demonstrated via pharmacological means a protective effect of ubiquitous proteasome inhibition (PSMI) against myocardial I/R injury. 18, [27] [28] [29] [30] To address this apparent discrepancy, we have established here the first tg mouse model of CR-PSMI and used it to test the impact of CR-PSMI on acute I/R injury in intact mice.
In the present study, we demonstrated that regional myocardial I/R induces PFI in cardiomyocytes of the heart. Second, we discovered that overexpression of a proteasedisabled missense (T60A) mutant precursor of ␤5 subunit in cardiomyocytes can effectively replace endogenous ␤5, and thereby inhibit proteasome chymotrypsin-like activity; thus, we established a stable tg mouse model of CR-PSMI. Finally, we demonstrated that moderate CR-PSMI is well tolerated by mice at the baseline condition but it augments the proapoptotic kinase protein kinase C␦ (PKC␦) and the phosphatase and tensin homolog (PTEN) signaling, suppresses PKC and the activation of prosurvival kinase Akt, aggravates cardiomyocyte apoptosis, and exacerbates myocardial I/R injury.
Methods
A detailed Methods section can be found in the Online Data Supplement.
Transgenic Mice
All mice used in this study are in the FVB/N inbred background. The creation and characterization of the tg mice with expression of a modified green fluorescence protein (GFPdgn) have been previously described. 21 GFPdgn was engineered via carboxyl fusion of degron CL1 to an enhanced green fluorescence protein (GFP) and is a proven substrate for the UPS. 21, 31 To establish a genetic model of CR-PSMI, we created stable tg mouse lines that overexpress a Myc-tagged missense mutation (T60A) of the murine precursor of ␤5 subunit of the 20S proteasome (hereafter known as T60A-␤5) under the control of an attenuated murine mhc6 promoter. The latter consists of a full-length mhc6 promoter in which 3 GATA sites and 2 TREs (thyroid response elements) were ablated but other cis-acting regions important for cardiac-specific expression were left intact. 32 
Left Ventricular Pressure-Volume Relationship Analysis
To assess the left ventricular (LV) pressure-volume (P-V) relationship, mice were anesthetized with isoflurane (2%) in medical-grade oxygen, then intubated and mechanically ventilated. The LV was catheterized via the right carotid artery with a 1.2-F mouse P-V catheter (Scisense, London, Ontario). The instrumented animal was stabilized for 10 minutes, and data were then recorded with a sampling rate of 1500 Hz with Ponemah software (Data Sciences International, Valley View, OH) during steady-state conditions. For subsequent analysis of P-V loops Ponemah software was used. The raw conductance volumes were corrected for parallel conductance by the hypertonic saline bolus. 
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In Vivo Myocardial I/R and Assessment of Infarct Size
Regional myocardial I/R was modeled in mice by surgical ligation of the left anterior descending coronary artery (LAD) for 30 minutes followed by releasing of the ligation for 24 hours. Determined by pilot studies, this protocol yields an average area at risk (AAR) of 40% and an average infarct size of 55% in young wild-type FVB/N mice (Online Figure I) . Infarct size was determined as previously reported. 26 
Terminal Deoxynucleotidyl Transferase End-Labeling Assay
The heart was excised 24 hours after reperfusion. Two tissue samples corresponding respectively to the AAR and the remote area (RA) of the LV free wall were collected, fixed in 4% paraformaldehyde in PBS for 24 hours at 4°C, and further processed for terminal deoxynucleotidyl transferase end-labeling (TUNEL) assays as previously described. 4 
Statistical Analysis
All continuous variables are presented as meanϮSD. Differences between 2 groups were evaluated for statistical significance using a 2-tailed Student t test. When difference among 3 or more groups was evaluated, 1-way ANOVA, or, when appropriate, 2-way ANOVA followed by the Holm-Sidak test for pairwise comparisons, was performed. Probability values Ͻ0.05 were considered statistically significant.
Results
PFI in the Heart of Mice With Acute Focal Myocardial I/R
To determine the impact of acute myocardial I/R on cardiac proteasome function, GFPdgn tg mice were subject to surgical LAD ligation for 30 minutes followed by release of the ligation to allow reperfusion. At 24 hours after reperfusion, myocardial samples were collected respectively from AAR (the area that had undergone ischemia during coronary ligation), the remote area (RA), and the border zone (BZ, a 1-mm-wide zone between AAR and RA) of the LV free wall for assessing proteasome peptidase activities and the steadystate ubiquitinated proteins. For the sham surgery control group, the tissue of the entire LV free wall was collected.
Crude protein extracts were used for measuring 20S proteasome peptidase activities. All 3 peptidase activities were significantly decreased in all the three zones of I/R hearts, compared with the sham controls ( Figure 1A ). The total ubiquitinated proteins, especially the high-molecular-weight species, were significantly increased in all zones of I/R hearts, compared with the sham controls ( Figure 1B and 1C).
To test if the decreased proteasome peptidase activities affect on UPS proteolytic function, we measured cardiac expression of GFPdgn, a surrogate protein substrate for the UPS. A significant increase in GFPdgn protein levels in all 3 zones of I/R hearts was observed quantitatively using Western blot analyses (Figure 2A and 2B) and qualitatively via confocal microscopy ( Figure 2C ). RT-PCR analyses demonstrated that the steady-state GFPdgn mRNA levels were not increased ( Figure 2D and 2E). In the absence of increases in synthesis, the increased GFPdgn protein levels indicate that the removal of abnormal proteins by the UPS is impaired. This impairment is presumably caused by PFI because 20S proteasome peptidase activities were significantly decreased in the I/R hearts.
Establishment of a Mouse Model of Moderate CR-PSMI
To date, no animal model of CR-PSMI has been reported, but such a model would benefit remarkably investigation into the pathophysiological significance of PFI in cardiomyocytes of intact animals. Hence, we sought to create one.
As mentioned earlier, proteasome peptidase activities reside in ␤1, ␤2, and ␤5 subunits of the 20S. The N-terminal threonine of the 3 matured ␤-subunits performs the nucleophilic attack for peptide bond hydrolysis. 33 The catalytically active N-terminal threonine residue resides in the interior face of the 20S chamber. 34 The C termini of ␤ subunits are on the outer surface of proteasomes so that carboxyl fusion of an "epitope tags" to a ␤ subunit would not affect the configuration and presumably activity of the proteasome. 35, 36 In both yeast and cultured mammalian cells, the activity of ␤5 subunit appears to be the most important component for proteasome activities. For proteasome assembly and maturation the hierarchy of importance among the 3 proteolytic subunits is ␤5Ͼ␤2Ͼ␤1. 36 -38 Thus, we decided to create a catalytically inactive mutant ␤5 subunit through mutating its N-terminal catalytic threonine to alanine. All 3 peptidase subunits are synthesized in the cell as precursors. The N-terminus is posttranslationally processed by autocatalytic activities during proteasome assembly and maturation, which exposes the N-terminal threonine. Various mutation studies further confirmed the importance of Thr76 in ␤5 precursor of yeast (also known as pre2). Replacing Thr76 with Ala (T76A) in pre2 decreased its chymotrypsin-like activity markedly but had little effect on trypsin-like and caspase-like activities. 36, 37 This indicates that T76A-pre2 can incorporate into the 20S proteasome, functioning as a dominant negative mutant.
Alignment of ␤5 sequences across species shows that T60 of mouse ␤5 (Psmb5) corresponds to T76 of yeast pre2. Thus, we chose to create a T60A-␤5 from mouse wild-type (WT-) ␤5 precursor cDNA. We differentiated T60A-␤5 from endogenous ␤5, with addition of a myc tag to the carboxyl terminus of T60A-␤5. Our pilot studies confirmed that overexpression of T60A-␤5 in mammalian cell lines and neonatal rat ventricular myocytes led to expression level-dependent decreases in the chymotrypsin-like activity and inhibition of proteasomal proteolytic function (data not shown). Hence, we generated stable tg mouse lines that overexpress myc-tagged T60A-␤5 precursor under the control of an attenuated mouse Mhc6 promoter ( Figure 3A ). Basic characterization of these mice revealed that overexpressed T60A-␤5 precursor was successfully converted to mature T60A-␤5, decreased endogenous ␤5 ( Figure 3B and 3C) , incorporated into the 20S proteasome as revealed by coimmunoprecipitation with the endogenous ␤5 and ␣4 subunits of the 20S ( Figure 3D) , and decreased the chymotrypsin-like activity in the heart by approximately 60% and 65% in tg line 1 and line 2, respectively ( Figure 3E ). Immunofluorescence confocal microscopy revealed that myc-T60A-␤5 proteins are enriched in the nucleus and at the Z-line levels in the cytoplasm (Online Figure II) , demonstrating the distribution pattern of endogenous 20S proteasomes observed in the cardiomyocytes. 39 No abnormality in cardiac function, morphology, or growth was detected during the first 6 months of life of these tg mouse lines (data not shown). Consistent with the moderate nature of CR-PSMI in these tg lines, myocardial total ubiquitinated proteins in T60A-␤5 tg mice at the baseline do not differ from Ntg littermates (Online Figure III) . Notably, as described above, both tg lines exhibit the same phenotype. The experiments described hereafter used tg line 1.
Moderate CR-PSMI Exacerbates Cardiac Dysfunction in I/R Mice
To determine the effect of CR-PSMI on I/R injury, T60A-␤5 tg and non-tg (Ntg) littermate mice were subject to the ischemia (30 minutes) and reperfusion (24 hours) protocol as described above. To verify T60A-␤5 expression and its impact on proteasome function in the AAR, BZ, and RA of I/R hearts, we assessed the expression of endogenous ␤5 and tg T60A-␤5 proteins and the changes of the activities of the ␤5-dependent and ␤5-independent peptidases (Figure 4) . Compared with Ntg sham, endogenous ␤5 protein levels were significantly decreased in the AAR and BZ but not RA of the Ntg I/R hearts. Compared with the tg sham, both endogenous ␤5 and tg T60A-␤5 proteins were expressed at a relatively lower level in all 3 zones of I/R hearts ( Figure 4A and 4B) . As a result, ␤5-dependent chymotrypsin-like activities were markedly lower in all 3 zones of I/R hearts in the T60A-␤5 tg mice than the Ntg mice ( Figure 4C ). Proteasome caspase-like activities, which are ␤5-independent, showed no significant difference between the tg and the Ntg groups ( Figure 4D) .
In a separate cohort, LV function was measured at the terminal experiment using P-V relationship analysis. As summarized in the Table and illustrated stolic function. The systolic function impairment was reflected by significant decreases in LV end-systolic pressure (Pes), the maximal rate of pressure increasing (dP/dt max ), ejection fraction (EF), stroke work (SW), and the preloadrecruited stroke work (PRSW) and by significant increases in end-systolic volume (Ves). The impairment of diastolic function was indicated by significant increases in end-diastolic pressure (Ped) and Tau and by decreases in the maximal rate of pressure decreasing (dP/dt min ). As a result, both stoke volume (SV) and cardiac output per minute (CO) were significantly smaller in the Ntg I/R group, compared with the Ntg sham group. Importantly, the I/R induced changes in all parameters except Tau were significantly exacerbated in the T60A-␤5 Tg I/R group. These findings demonstrate that CR-PSMI aggravates cardiac malfunction induced by regional myocardial I/R. 
Moderate CR-PSMI Increases Infarct Size and Cardiomyocyte Apoptosis in I/R Hearts
Ischemia and infarct size determination showed that the LAD ligation induced ischemic area or AAR was not significantly different between the Ntg I/R and the Tg I/R groups but at 24 hours after reperfusion, the infarct size of the Tg I/R group was significantly greater than that of the Ntg I/R group ( Figure 5 ). These results indicate further that moderate CR-PSMI exacerbates I/R injury.
To explore the potential mechanism underlying the detrimental effect of moderate CR-PSMI on I/R hearts, we first examined the prevalence of cardiomyocyte apoptosis via the TUNEL assay and the detection of activated/cleaved caspase 3 in various areas of the LV. Essentially no TUNEL positive cardiomyocytes were detected in Ntg or Tg sham control hearts but I/R induced an increase in TUNEL positive cardiomyocytes in the AAR and the remote areas of both Ntg and Tg hearts. The increases were more pronounced in the T60A-␤5 Tg I/R hearts than Ntg I/R hearts ( Figure 6A and 6B). Western blot analysis revealed that the level of cleaved caspase3 was significantly increased in the AAR, BZ, and RA of the I/R hearts of Ntg and Tg groups. The increase was more pronounced in the T60A-␤5 Tg hearts than Ntg hearts ( Figure 6C and 6D) .
Moderate CR-PSMI Augments PKC␦ and PTEN and Suppresses PKC and Akt Activation
Akt activation and PKC protect against myocardial I/R injury, whereas increased expression of PTEN and PKC␦ does the opposite at least in part through suppressing Akt. 40, 41 These key signaling molecules are degraded by the UPS. Hence, in a separate cohort, we probed Akt activation through measuring Ser473-phospophrylated Akt (pS473-Akt) protein levels and measured the steady state protein levels of PTEN, Akt, PKC␦, and PKC in LV regions that were differentially affected by LAD ligation/release. Compared with the Ntg sham group, PTEN protein levels were significantly higher and pS473-Akt levels were markedly lower in the T60A-␤5 Tg sham group. I/R triggered marked decreases in PTEN in all three regions of the Ntg hearts, but the decrease was completely reversed in RA and significantly attenuated in BZ and AAR by CR-PSMI ( Figure 7A and 7C) . I/R triggered a marked increase in pS473-Akt in all the three regions of the Ntg hearts but this increase was completely blocked by CR-PSMI ( Figure 7A and 7B). PKC␦ was significantly higher but PKC remained unchanged in the T60A-␤5 Tg sham group, compared with the Ntg sham group. I/R triggered an upregulation of PKC␦ in all the 3 zones of the Ntg hearts, and this upregulation was significantly enhanced by moderate CR-PSMI ( Figure 7D and 7E). I/R did not alter PKC levels in the RA but tended to downregulate PKC in the BZ and significantly downregulated PKC in the AAR of Ntg hearts. The downregulation of PKC in the BZ and AAR was aggravated by CR-PSMI ( Figure 7D and 7F).
Discussion
Myocardial I/R injury is an important pathological process occurring both in the natural course and during the intervention (eg, revascularization) of ischemic heart disease, in addition to heart transplantation. 42 Although significant progress has been made toward understanding I/R injury the molecular mechanisms underlying I/R are incompletely understood, and finding effective clinical intervention to reduce the injury remains an important challenge. 42 Several previous studies have suggested a role of altered cardiac proteasome function in I/R injury 20, 24, 26, 28, 30 ; however, these reports often contradict one another, regarding the adequacy of the altered proteasome function in maintaining cardiac proteostasis during I/R and the feasibility to inhibit proteasome function for ameliorating I/R injury. 16, 29, 30 Taking advantage of a previously validated UPS reporter mouse, we demonstrated here for the first time that PFI occurs in mouse hearts undergoing regional myocardial I/R. Moreover, we established the first animal model of CR-PSMI and used this model to illustrate that a moderate inhibition of proteasome function in cardiomyocytes can be tolerated in mice at the baseline condition but it remarkably exacerbates I/R injury potentially via increasing PTEN and PKC␦ protein levels, suppressing PKC and Akt signaling, and increasing cardiomyocyte death.
PFI in Cardiomyocytes of I/R Hearts
In previous reports, proteasome functional status in I/R hearts was assessed primarily by measuring proteasome peptidase activities, the expression of some proteasome subunits, and the abundance of ubiquitin conjugates. Virtually all reports showed increases in ubiquitin conjugates. Most reports showed decreased 20S proteasome activities in I/R hearts. We confirmed these findings in the GFPdgn tg mouse LV with regional I/R. The decreases of proteasome peptidase activities observed in I/R myocardium are likely attributable to both decreased proteasome abundance, as evidenced by the decreases of ␤5 in both the BZ and AAR of Ntg I/R hearts and posttranslational modifications such as oxidation of proteasome subunits as previously reported. 17, 20 Notably, the degree (10%Ϸ40%) of decreases in the 20S proteasome peptidase activities observed in the RA, BZ, and AAR of I/R hearts alone should not be sufficient to impair the degradation of native proteins if the terminally damaged/misfolded proteins, which need proteasomes for their removal, are not increased. This is because previous reports have shown that it takes much more severe inhibition of the 20S proteasome (Ϸ75%) to accumulate surrogate proteasome substrates. 21, 43 During I/R, the production of terminally misfolded/damaged proteins (eg, oxidized proteins) is inevitably increased; hence, the global increase of ubiquitinated proteins in I/R hearts is consistent with PFI but does not necessarily demonstrate PFI. This is because global increases of ubiquitinated proteins in the cell can also be caused by many other factors, such as increased production of ubiquitinated proteins (ie, increased ubiquitination), decreased deubiquitination, increased atypical ubiquitination that yields ubiquitinated proteins not degradable by the proteasome, and impaired macroautophagy. 2 Therefore, we probed the sufficiency of UPS function using GFPdgn, a validated surrogate substrate for the UPS.
To our surprise, besides in cardiomyocytes of the AAR and the BZ, GFPdgn was also accumulated in cardiomyocytes of the RA, where blood perfusion was not manipulated. These findings indicate that PFI occurs in the cardiomyocytes of I/R hearts.
Moderate CR-PSMI Is Well Tolerated at the Baseline But Is Detrimental During I/R
Multiple pharmacological agents are capable of inhibiting proteasome function and a pharmacological approach can have a few advantages. It is relatively cost-and time-efficient and easier to achieve different degrees of inhibition. However, it is extremely difficult, if not impossible, to achieve homogeneous CR-PSMI in intact animals without affecting proteasomal function in other tissues and organs using pharmacological inhibitors, regardless of the specificity issues of proteasome inhibitors. Therefore, a genetic approach to specifically inhibit the 20S proteasome fulfills the purpose of this study better.
In the present study, we created the first tg mouse model of CR-PSMI via cardiac overexpression of a dominant negative mutant ␤5 subunit. Our baseline characterization on cardiac growth/development, the fetal gene program, and heart function of these mice (data not shown) has revealed that moderate CR-PSMI does not cause discernible abnormal phenotype in mice during the first 6 months of life (the longest time observed). However, CR-PSMI exacerbates myocardial I/R induced cardiac functional and structural impairment. At the function side, our P-V relationship analysis showed that at 24 hours of reperfusion after 30 minutes of ischemia, as expected, Ntg mice displayed significant decreases in both LV contractility and relaxation. The I/R induced LV functional impairment, especially the systolic malfunction, was more pronounced in T60A-␤5 tg mice. Similarly, the same I/R procedure caused a greater infarct size in T60A-␤5 tg mice than Ntg littermates. Consistent with these findings, chemotherapy using proteasome inhibitor bortezomib is generally well tolerated by multiple myeloma patients without preexisting cardiac conditions, whereas the therapy was associated with the development of heart failure and other cardiac dysfunction in elderly patients or patients with preexisting cardiac conditions. 44, 45 The present findings are also in agreement with our recent report that cardiomyocyte-restricted proteasome functional enhancement via PA28␣ overexpression protects against I/R injury in mice. 26 Taken together, through both gain-of-function (our previous study) and loss-of-function (the present study) approaches, we have now demonstrated that PFI in cardiomyocytes contributes to myocardial I/R injury. This conclusion is indirectly supported by several recent studies that suggest preserving cardiac proteasome function protects against I/R injury. 16, 19 Notably, the above conclusion appears to tangentially dispute several previous reports that show a protective effect of proteasome inhibitors on I/R hearts in vivo or ex vivo. 27, 28, 30 This is because PSMI in the present study is cardiomyocyte-restricted, whereas the previously reported in vivo PSMI was achieved by systemic administration of pharmacological inhibitors and was ubiquitous to the body and/or to all tissue/cell types of the heart. Inflammation and the innate immune responses play a major role in I/R injury. 42 Indeed, there is evidence that the protective effect of pharmacological PSMI observed in previous studies is attributable to its anti-inflammatory effects, 28, 30 such as inhibition of the NFB pathway and leukocyte infiltration. 27, 30 Apparently, noncardiomyocyte compartments of the heart (eg, vasculature) and other systems (eg, leukocytes and the immune system) play an important role in I/R associated inflammatory responses. In aggregate, it is suggested that the benefit of ubiquitous PSMI during myocardial I/R is derived primarily from the inhibition of proteasomes in noncardiomyocytes. Hence, it is reasonable to speculate that measures to selectively inhibit the proteasome in noncardiomyocyte compartments would be more effective in protecting against myocardial I/R injury than ubiquitous PSMI.
Potential Mechanisms Underlying the Detrimental Effect of CR-PSMI
Oxidative stress is markedly increased during reperfusion, 42 resulting in a burst of production of oxidized proteins, including oxidative modifications of proteasome subunits and thereby inhibiting proteasome function. 20, 24 The removal of oxidized proteins is 20S proteasome dependent. 46 -49 Therefore, it is not surprising that PFI occurs in the cardiomyocytes of I/R hearts. Hence, as supported by the findings that I/R triggered increases of total ubiquitinated proteins were remarkably aggravated by CR-PSMI (Online Figure V) , additional CR-PSMI further impairs the degradation of oxidized/misfolded proteins in cardiomyocytes, exacerbating cardiomyocyte dysfunction and even causing cell death. Indeed, both TUNEL assays and detection of activated form of caspase 3 revealed that CR-PSMI significantly increased the prevalence of apoptotic cardiomyocytes in I/R hearts.
Beyond PQC, UPS-mediated protein degradation also regulates cell signaling pathways. PTEN is degraded by the UPS, and it negatively regulates Akt. The Akt-mediated prosurvival signaling is activated and plays a protective role during myocardial I/R. 40 The effect of PSMI on PTEN and Akt activation in the cardiomyocytes of I/R hearts has rarely been reported. 16 In the present study, we found that myocardial PTEN was significantly increased, and consistently, Akt activation was suppressed by moderate CR-PSMI in mice under the basal condition (Online Figure VI) . Moreover, Akt activation during I/R, as indicated by the increase of Ser473-phosphorylated Akt, was abolished by moderate CR-PSMI. This is perhaps mediated by increased expression of PTEN and PKC␦ as both PTEN and PKC␦ can inhibit Akt. 42 These results suggest that suppressing Akt activation may have contributed to CR-PSMI induced increases in cardiomyocyte apoptosis in I/R hearts. Ischemic preconditioning (IPC) can powerfully protect against subsequent I/R injury. Two recent reports suggest that preservation of proteasome function contributes to the IPC protection. 16, 20 By activating on the mitochondrial pathway of cell death, PKC␦ is a well-known mediator of I/R injury, 50 whereas PKC protects against I/R injury. 41 It was shown that IPC enhanced PKC␦ degradation by the UPS and pharmacologically induced PSMI resulted in mitochondrial accumulation of PKC␦ and a loss of IPC protective effects. 16 In the present study, we observed that genetically induced CR-PSMI increased the abundance of PKC␦ and decreased PKC in I/R hearts, suggesting that CR-PSMI induced exacerbation of I/R injury might also be related to upregulation of PKC␦ and downregulation of PKC in the heart. In summary, the present study demonstrates that PFI occurs in cardiomyocytes during myocardial I/R, that moderate CR-PSMI exacerbates cardiac dysfunction and cardiomyocyte death during regional myocardial I/R, and that the detrimental effects of CR-PSMI during myocardial I/R are associated with suppressing the activation of prosurvival kinase Akt and PKC while enhancing proapoptotic pathways mediated by PKC␦.
